Evotec SE (EVO) 股票分析

公司概述

Evotec SE functions as a specialized drug discovery and development entity operating across the United States, Germany, France, the United Kingdom, Switzerland, and international markets through two primary segments: Shared R&D and Just Evotec Biologics. The company is positioned within the Healthcare sector, specifically classified under the Drug Manufacturers - Specialty & Generic industry, indicating its focus on creating and commercializing pharmaceutical solutions for niche and generic therapeutic areas. As of the latest reporting period, the company carries a market capitalization of $937.80M and generated annual revenue of $788.37M, though specific employee count data is not currently disclosed. These financial dimensions suggest Evotec SE maintains a mid-cap profile with significant revenue generation capabilities relative to its market size, reflecting a substantial operational footprint in the global pharmaceutical supply chain. The scale of its operations, evidenced by nearly $790M in revenue and a market cap exceeding $900M, underscores its established role as a key player in the broader healthcare ecosystem rather than a nascent startup.

财务健康

Evotec SE reported a trailing twelve-month revenue of $788.37M, yet the company recorded a net income loss of $-103,517,000 and an EBITDA of $43.89M. The substantial discrepancy between the positive revenue figure and the significant net loss reveals a cost structure characterized by high operating expenses or non-operating charges that erode profitability despite top-line growth. While the EBITDA remains positive at $43.89M, the company's free cash flow stands at $-53,830,376, indicating a cash burn situation that impacts immediate financial flexibility and capital allocation strategies. The company's margins reflect this financial pressure, with a gross margin of 14.5%, an operating margin of 13.3%, and a negative profit margin of -13.1%, signaling that while production costs are contained relative to sales, overall profitability is currently compromised. On the balance sheet, Evotec SE holds $476.39M in cash against $448.73M in debt, resulting in a debt-to-equity ratio of 55.15, which suggests a leveraged position where debt levels are nearly equal to available liquid assets. Despite the leverage, the current ratio of 2.07 indicates a robust short-term liquidity position, as current assets are more than double current liabilities. Furthermore, the return on equity is -11.7% and the return on assets is -1.9%, metrics that demonstrate management's current inability to generate positive returns on the capital base deployed in the business.

估值评估

The valuation metrics present a mixed picture, with a trailing P/E ratio listed as N/A due to the net loss, while the forward P/E is reported at -13.79, implying that future earnings projections are currently negative or insufficient to support a traditional multiple. The price-to-book ratio stands at 1.01, indicating that the market values the company at approximately its book value without a significant premium or discount. Additionally, the price-to-sales ratio is 1.19 and the EV/EBITDA is 9.97, suggesting that investors are pricing the stock based on sales multiples and enterprise value relative to earnings before interest, taxes, depreciation, and amortization rather than traditional earnings multiples. In terms of trading range, the stock's 52-week high is $4.80 and the 52-week low is $2.31, with the current price situated somewhere within this historical band. The beta value is N/A, meaning there is no available data to quantify the stock's volatility relative to the broader market movements. These alternative valuation metrics, such as the P/S and EV/EBITDA, are particularly relevant for capital-intensive biotechnology and pharmaceutical firms where earnings may be negative during development phases.

Growth & Income

Evotec SE achieved a revenue growth rate of 14.5% year-over-year, while earnings growth is N/A due to the company's current net loss status. The divergence between strong revenue expansion and the absence of earnings growth implies that top-line gains are currently being absorbed by fixed costs or R&D expenditures rather than flowing through to the bottom line. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that it reinvests all available earnings and cash flows back into research and development or operational expansion rather than distributing income to shareholders. Consequently, the overall growth and income profile is defined by aggressive revenue expansion funded by internal cash reserves and external financing, with no current reliance on dividend income for shareholders.